Valuation: Genmab A/S

Market Cap 221B 32.5B 29.61B 27.41B 24.79B 46.51B 3,035B 48.68B 331B 131B 1,640B 122B 119B 5,196B P/E 2026 *
41.5x
P/E 2027 * 32.4x
Enterprise Value 240B 35.28B 32.14B 29.76B 26.92B 50.49B 3,295B 52.85B 360B 143B 1,781B 132B 130B 5,640B EV / Sales 2026 *
8.01x
EV / Sales 2027 * 6.42x
Free-Float
94.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.10%
1 week+1.51%
Current month-10.53%
1 month+34.51%
3 months+63.48%
6 months+103.19%
Current year+72.67%
1 week 3,450
Extreme 3450
3,582
1 month 2,586
Extreme 2586
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+1.51%+78.85%+57.66% 32.5B
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.16%-2.48%+6.67%+90.06% 58.91B
-2.07%-1.95%+23.21%+82.81% 55.24B
-0.48%-4.88%+13.44%+110.90% 45.66B
-0.44%-5.56%+15.32%+21.96% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+4.40%-3.57%+137.75%+664.57% 34.48B
-0.43%+20.81%-26.68%+494.54% 31.69B
-6.57%-16.20%+28.32%-13.31% 22.93B
Average -0.92%-1.62%+34.88%+161.92% 42B
Weighted average by Cap. -0.88%-1.77%+33.29%+145.70%

Financials

2026 *2027 *
Net sales 29.99B 4.4B 4.01B 3.71B 3.36B 6.3B 411B 6.6B 44.89B 17.81B 222B 16.52B 16.17B 704B 36.34B 5.34B 4.86B 4.5B 4.07B 7.64B 498B 7.99B 54.4B 21.58B 269B 20.02B 19.6B 853B
Net income 5.33B 783M 713M 660M 597M 1.12B 73.1B 1.17B 7.98B 3.17B 39.5B 2.94B 2.87B 125B 7.05B 1.03B 943M 873M 789M 1.48B 96.63B 1.55B 10.55B 4.18B 52.22B 3.88B 3.8B 165B
Net Debt 18.93B 2.78B 2.53B 2.34B 2.12B 3.98B 260B 4.16B 28.34B 11.24B 140B 10.43B 10.21B 444B 11.78B 1.73B 1.58B 1.46B 1.32B 2.48B 162B 2.59B 17.64B 7B 87.33B 6.49B 6.36B 277B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
20/11/26 DKK 3,503.00 +0.17% 42,577
19/11/26 DKK 3,497.00 +0.03% 119,495
18/11/26 DKK 3,496.00 -0.17% 114,462
17/11/26 DKK 3,502.00 -0.77% 152,354
16/11/26 DKK 3,529.00 +2.35% 152,134
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,497.00DKK
Average target price
4,195.23DKK
Spread / Average Target
+19.97%
  1. Stock Market
  2. Stocks
  3. GMAB Stock